Senti Biosciences (SNTI) appoints Feng Hsiung to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Senti Bio Appoints Feng Hsiung to Board of Directors
March 13, 2025 4:01 PM EDTSOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (Senti Bio, or the Company), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the Board).
We are pleased to welcome Feng to our Boardhe brings deep expertise in investment strategy and capital markets across multiple industries, said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. We look... More
